In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Immutep (IMMP - Research Report), with a price target of $8.00. The company's shares opened today at $1.82.According to TipRanks, McCarthy is an analyst with an average return of -39.0% and a 13.21% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Mesoblast, Atossa Therapeutics, and Capricor Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immutep with a $8.00 average price target.
https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-immutep-immp?utm_source=advfn.com&utm_medium=referral
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Immutep Charts.
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Immutep Charts.